Form 4: Quoin Pharmaceuticals COO Denise Carter Increases Stake in Company
SEC Form 4 Filing
Denise Carter, COO of Quoin Pharmaceuticals, recently acquired additional ordinary shares in the company through a series of transactions.
Summary
- Denise Carter, the Chief Operating Officer of Quoin Pharmaceuticals, has reported changes in her beneficial ownership of the company's ordinary shares.
- On September 3, 2024, she acquired 1,822 shares at $0.6253 and 4,100 shares at $0.6551.
- On September 4, 2024, she acquired 8,825 shares at $0.7481 and 22,988 shares at $0.7965.
- Following these transactions, Carter directly owns 47,092 ordinary shares.
- These transactions were reported on a Form 4 filing with the SEC.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. Insider buying can be seen as a positive signal, but it's a relatively small transaction and could be for various reasons.
Positives
- The COO's increased investment could be interpreted as a positive signal about her confidence in the company's future prospects.
Industry Context
Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company insiders.
Stakeholder Impact
- Shareholders may view the COO's increased stake as a positive sign of confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| July 18, 2023 | Ratio of ADSs evidencing ordinary shares changed from 1 ADS representing five thousand (5,000) ordinary shares to 1 ADS representing sixty thousand (60,000) ordinary shares, which resulted in a 1 for 12 reverse split of the issued and outstanding ADSs. |
| November 8, 2023 | The Issuer completed a 1 for 60,000 reverse split of the ordinary shares which resulted in the ratio of ADSs evidencing ordinary shares to be changed from 1 ADS representing sixty thousand (60,000) ordinary shares to 1 ADS representing one (1) ordinary share. |
| September 3, 2024 | Denise Carter acquired 1,822 ordinary shares at $0.6253 and 4,100 ordinary shares at $0.6551. |
| September 4, 2024 | Denise Carter acquired 8,825 ordinary shares at $0.7481 and 22,988 ordinary shares at $0.7965. |
| September 5, 2024 | Date of signature for the SEC Form 4 filing. |
Keywords
Quoin Pharmaceuticals, Denise Carter, ordinary shares, beneficial ownership, SEC Form 4, QNRX, acquisition
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.